Dr. Reddy’s secures EUA for Sputnik V vaccine in India for Covid-19 prevention

TAGS

Dr. Reddy’s Laboratories has secured permission from the Drug Controller General of India (DCGI) for importing the Sputnik V vaccine into India under emergency use authorization (EUA).

In February 2021, Dr. Reddy’s Laboratories commenced the process to seek the emergency use authorization for the Russian Covid-19 vaccine from the Indian drug regulator.

Last September 2020, Dr. Reddy’s Laboratories entered into a partnership with the Russian Direct Investment Fund (RDIF) for undertaking Sputnik V clinical trials and for distribution of the vaccine in India.

See also  IMCD buys polymers and engineering plastics distributor Tradeimpex Polymers

Apart from the clinical trials held in Russia by RDIF, phase 2/3 trials of the Covid-19 vaccine were taken up in India by Dr. Reddy’s Laboratories.

Dr. Reddy's Laboratories secures EUA for Sputnik V vaccine in India for Covid-19 prevention

Dr. Reddy’s Laboratories secures EUA for Sputnik V vaccine in India for Covid-19 prevention. Photo courtesy of The Russian Direct Investment Fund.

GV Prasad – Dr Reddy’s Laboratories Co-chairman and managing director said: “We are very pleased to obtain the emergency use authorsation for Sputnik V in India. With the rising cases in India, vaccination is the most effective tool in our battle against COVID-19. This will enable us to contribute to our nation’s effort of vaccinating a signficant proportion of our population.”

See also  JK Tyre & Industries wraps up phase 1 of Rs 1,000cr Banmore facility expansion

Currently, the Sputnik V vaccine is approved for use in 60 countries. The Russian Covid-19 vaccine uses a couple of different vectors for the two shots in its vaccination course.

Sputnik V efficacy was established to be 91.6% as per a published article in the Lancet medical journal.

CATEGORIES
TAGS
Share This